High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT
K Rezvani, S Mielke, M Ahmadzadeh, Y Kilical… - Blood, 2006 - ashpublications.org
Regulatory T cells (T reg s) that constitutively express FOXP3 are instrumental to the
maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans. To …
maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans. To …
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
K Rezvani, ASM Yong, S Mielke… - Blood, The Journal …, 2008 - ashpublications.org
We describe the safety and immunogenicity of a combined vaccine of 2 leukemia-associated
antigenic peptides, PR1 and WT1. Eight patients with myeloid malignancies received one …
antigenic peptides, PR1 and WT1. Eight patients with myeloid malignancies received one …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm …
…, SR Foley, JR Westin, I Fleury, PJ Ho, S Mielke… - The Lancet …, 2021 - thelancet.com
Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response …
anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response …
Large-scale GMP-compliant CRISPR-Cas9–mediated deletion of the glucocorticoid receptor in multivirus-specific T cells
…, S Acharya, NW Fowlkes, J Lu, S Li, S Mielke… - Blood …, 2020 - ashpublications.org
Virus-specific T cells have proven highly effective for the treatment of severe and drug-refractory
infections after hematopoietic stem cell transplant (HSCT). However, the efficacy of …
infections after hematopoietic stem cell transplant (HSCT). However, the efficacy of …
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen …
S Mielke, R Nunes, K Rezvani… - Blood, The Journal …, 2008 - ashpublications.org
Selective allodepletion is a strategy to eliminate host-reactive donor T cells from hematopoietic
stem cell allografts to prevent graft-versus-host disease while conserving useful donor …
stem cell allografts to prevent graft-versus-host disease while conserving useful donor …
[HTML][HTML] Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
…, V Bachanova, SR Foley, PJ Ho, S Mielke… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. …
second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. …
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients …
…, B Glass, V Bachanova, S Ibrahimi, S Mielke… - The Lancet, 2022 - thelancet.com
Background Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed
within 12 months of first-line therapy are at high risk for poor outcomes with current standard of …
within 12 months of first-line therapy are at high risk for poor outcomes with current standard of …
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
…, A Schmitt-Gräff, W van der Velden, G Huls, S Mielke… - Leukemia, 2015 - nature.com
Despite major improvements in allogeneic hematopoietic cell transplantation over the past
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (…
decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (…
[HTML][HTML] International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International …
…, S Goldstein, M Jagasia, F Locatelli, S Mielke… - Biology of Blood and …, 2016 - Elsevier
Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse
mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD …
mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD …
Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf …
…, AR Zander, D Bunjes, S Mielke… - Journal of Hematology & …, 2017 - Springer
Background Primary refractory acute myeloid leukemia (PRF-AML) is associated with a dismal
prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative …
prognosis. Allogeneic stem cell transplantation (HSCT) in active disease is an alternative …
